Moderna and Merck mRNA cancer vaccine shows success in Phase 3 melanoma trial
Moderna and Merck have announced positive results from a Phase 3 clinical trial of their mRNA-based cancer vaccine targeting melanoma. The vaccine demonstrated effectiveness in preventing the recurrence and spread of the cancer. This marks a significant milestone in the development of personalized mRNA cancer therapies, building on the same technology platform used in COVID-19 vaccines. The trial's success brings the experimental treatment closer to potential regulatory approval and broader clinical use.






